Weight loss through lifestyle interventions clearly improves metabolic factors associated with obesity as well as conditions coexisting with obesity, warranting its use as a first-line treatment
(5) Specifically, the researchers commented that 12-hour mean growth hormone concentration increased from 1.1 0.9 g/L to 2.2 1.9 g/L, and the integrated growth hormone secretion over 12 hours
Cho, S., Rasoulianboroujeni, M., Kang, R
Precautions: Do not exceed the recommended daily serving
Neuroscience & Biobehavioral Reviews, 6 (2), 177182
WHAT IS CAGRILINTIDE Cagrilintide is a synthetic, long-acting amylin analog peptide developed by Novo Nordisk as a potential treatment for obesity and related metabolic conditions